The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

HHS and the National Institutes of Health plan to develop universal vaccines targeting a broad range of flu and coronavirus strains using a new whole-virus platform. The platform, dubbed Generation ...